Jupiter Neurosciences Director Andrew Cutler Receives Option Award

What Happened

• Andrew Jon Cutler, a director of Jupiter Neurosciences (JUNS), was granted 472,222 stock options on 2026-07-31. The grant is reported as a derivative acquisition at $0.00 per option (no cash exchanged at grant). Each option represents the right to purchase one share under the Issuer's 2025 Equity Incentive Plan.

Key Details

• Transaction date and type: 2026-07-31 — Grant/Award (derivative), 472,222 options, reported at $0.00 per option.
• Vesting: 25% vests upfront; the remaining 75% vests in three quarterly installments beginning February 1, 2026, subject to continued service (per footnote F1).
• Purpose: Granted in connection with Cutler’s appointment to the Board and in lieu of cash board retainer and committee fees.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Filing date and timeliness: Form filed 2026-08-05 for a 2026-07-31 grant — this appears later than the standard two-business-day Form 4 deadline and may be a late filing.
• Footnote: F1 describes the grant mechanics (options = right to buy one share each under the 2025 plan) and the vesting/payment-in-lieu-of-cash detail.

Context

• This was an option grant (award), not a purchase or sale—no shares were acquired outright and no immediate cash proceeds occurred. Grants like this are common for new directors and are a form of compensation that vests over time; any future exercise or sale would generate a separate Form 4 disclosure.